Sarcoma

Osteosarcoma & Osteochondroma

Osteosarcoma

Osteosarcoma is a malignant primary bone tumor in which neoplastic mesenchymal cells produce osteoid—unmineralized organic bone matrix. This histologic requirement distinguishes osteosarcoma from other “small round blue cell” or cartilage-producing tumors. It is the most common primary malignant bone tumor of childhood and adolescence, with peak incidence at 10–20 years, corresponding to rapid longitudinal growth. A second smaller peak occurs in older adults, often associated with Paget disease of bone, prior radiation, or chronic bone infarcts.

The classic location is the metaphysis of long bones, especially around the knee: distal femur, proximal tibia, and proximal humerus. This reflects high osteoblastic activity at growth plates. Patients typically present with progressive localized bone pain, swelling, and sometimes pathologic fracture. Constitutional symptoms are usually absent, helping distinguish osteosarcoma from Ewing sarcoma.

Pathogenesis and High-Yield Genetics

• RB1 loss: hereditary retinoblastoma markedly increases osteosarcoma risk; RB normally restrains the G1-to-S cell-cycle transition by inhibiting E2F.
• TP53 mutations: seen in Li-Fraumeni syndrome; p53 normally mediates DNA-damage arrest and apoptosis.
• Radiation-induced osteosarcoma: typically arises years after exposure, often in irradiated bone.
• Paget disease: disorganized high-turnover bone in older adults predisposes to osteosarcoma transformation.

Grossly, osteosarcoma is destructive and infiltrative. Microscopically, malignant pleomorphic osteoblasts produce lace-like osteoid. Serum alkaline phosphatase and LDH may be elevated and correlate with tumor burden, but they are not diagnostic.

Feature	Osteosarcoma
Age	Adolescents; older adults with Paget disease/radiation
Site	Metaphysis, especially around knee
Radiograph	Mixed lytic/sclerotic lesion, aggressive periosteal reaction
Classic signs	Sunburst pattern and Codman triangle
Histology	Malignant cells producing osteoid
Metastasis	Hematogenous, especially lungs; skip lesions may occur within bone

The sunburst appearance results from spiculated periosteal new bone laid down perpendicular to the cortex. A Codman triangle forms when aggressive tumor lifts the periosteum, leaving a triangular rim of reactive bone. These are signs of aggressive bone pathology, not unique to osteosarcoma.

Staging and Treatment Principles

For Step 1, know that staging integrates grade, local extent, and metastasis. The Enneking system classifies malignant bone tumors by grade, compartment, and metastasis: stage I is low grade, stage II is high grade, and stage III has metastases. Most conventional osteosarcomas are high grade; localized extracompartmental tumors are often considered stage IIB. Approximately 10–20% have detectable metastases at diagnosis, most commonly pulmonary.

Modern therapy combines limb-sparing surgery with multiagent chemotherapy. The classic regimen is MAP: high-dose methotrexate, doxorubicin, and cisplatin. Representative pediatric dosing includes methotrexate 8–12 g/m² with leucovorin rescue, doxorubicin cumulative lifetime limit about 450–550 mg/m² because of cardiomyopathy risk, and cisplatin commonly 100–120 mg/m² per cycle depending on protocol. Methotrexate inhibits dihydrofolate reductase; doxorubicin intercalates DNA and generates free radicals; cisplatin forms DNA cross-links. Histologic response after neoadjuvant chemotherapy is prognostic: ≥90% tumor necrosis is considered a good response. Current cooperative group and NCCN-style approaches emphasize complete resection plus perioperative chemotherapy; landmark cooperative trials established that chemotherapy improved survival over surgery alone. Localized osteosarcoma has approximately 60–70% 5-year survival, whereas metastatic disease is closer to 20–30%.

Osteochondroma

Osteochondroma is the most common benign bone tumor. It is a cartilage-capped bony outgrowth, or exostosis, arising from the metaphysis of long bones. Unlike osteosarcoma, it is not a malignant osteoid-producing tumor. It represents disordered growth-plate cartilage that herniates through the periosteal bone collar and continues endochondral ossification away from the joint.

Radiographically, the key diagnostic feature is continuity of the lesion’s cortex and medullary cavity with the parent bone. The projection classically points away from the nearest joint. Common sites include the distal femur, proximal tibia, and proximal humerus. Most lesions present before age 20 years as a painless, hard mass; symptoms arise from mechanical irritation, fracture through the stalk, neurovascular compression, or bursa formation.

Feature	Solitary Osteochondroma	Hereditary Multiple Exostoses
Inheritance	Sporadic	Autosomal dominant
Genes	Usually isolated	EXT1 or EXT2
Mechanism	Aberrant growth-plate cartilage	Defective heparan sulfate synthesis affecting Indian hedgehog signaling
Malignant transformation	<1%	Approximately 1–5%, higher in some series

The major feared complication is transformation to secondary chondrosarcoma, suggested by new pain, growth after skeletal maturity, or a cartilage cap thicker than about 2 cm in adults on MRI. In children, the cartilage cap may normally be thicker, so interpretation depends on age and skeletal maturity. Management is observation for asymptomatic lesions and excision for symptomatic, enlarging, deforming, or suspicious lesions. For Step 1, the central contrast is: osteosarcoma is an aggressive malignant metaphyseal tumor producing osteoid, whereas osteochondroma is a benign metaphyseal exostosis with marrow continuity and a cartilage cap.

Ewing Sarcoma

Core Definition and Epidemiology

Ewing sarcoma is an aggressive malignant tumor of bone or soft tissue composed of primitive neuroectodermal “small round blue cells.” It is a high-yield pediatric bone tumor, classically affecting children and adolescents aged 10–20 years, with a slight male predominance and higher incidence in individuals of European ancestry. It most often arises in the diaphysis or metadiaphysis of long bones, especially the femur, tibia, and humerus, but also commonly involves flat bones such as the pelvis, ribs, and scapula.

Molecular Pathogenesis

The defining mechanism is a chromosomal translocation involving the EWSR1 gene on chromosome 22. In approximately 85%–90% of cases, the translocation is t(11;22)(q24;q12), producing an EWSR1-FLI1 fusion protein. Less commonly, t(21;22) creates an EWSR1-ERG fusion. These fusion proteins act as abnormal transcription factors, altering gene expression programs that promote proliferation, inhibit differentiation, and support invasion.

Feature	High-Yield Association
Genetic abnormality	t(11;22) → EWSR1-FLI1 fusion transcription factor
Age group	Children/adolescents, peak 10–20 years
Bone location	Diaphysis of long bones; pelvis/ribs also common
Histology	Small round blue cells, scant cytoplasm, high nuclear-to-cytoplasmic ratio
Immunohistochemistry	Strong membranous CD99; often nuclear FLI1

Clinical Presentation

Patients usually present with localized bone pain, swelling, and tenderness. Pain may be progressive, nocturnal, or worsened with activity. Because Ewing sarcoma often produces systemic inflammatory symptoms, it can mimic osteomyelitis: fever, malaise, elevated erythrocyte sedimentation rate, leukocytosis, and elevated lactate dehydrogenase may be present. Step 1 questions often emphasize a child with a painful diaphyseal mass plus fever, where biopsy reveals small round blue cells.

Imaging and Gross Pathology

Plain radiographs classically show a destructive, permeative lytic lesion in the diaphysis with a laminated periosteal reaction called an “onion-skin” appearance. This occurs because rapidly growing tumor repeatedly lifts the periosteum, and new layers of reactive bone form beneath it. A Codman triangle may also be seen but is not specific; it can occur in other aggressive bone tumors such as osteosarcoma.

Magnetic resonance imaging is used to define marrow and soft-tissue extension, while computed tomography of the chest helps assess pulmonary metastases. Bone scan or PET/CT may identify multifocal bone involvement. At diagnosis, approximately 20%–25% of patients have detectable metastatic disease, most commonly to the lungs, bone, and bone marrow.

Microscopic Features

On histology, Ewing sarcoma is composed of sheets of uniform small round cells with darkly staining nuclei and scant cytoplasm. The cytoplasm often contains abundant glycogen, making tumor cells PAS-positive and diastase-sensitive. Homer Wright pseudorosettes may be present, reflecting primitive neural differentiation. Molecular confirmation by fluorescence in situ hybridization or reverse-transcription PCR for EWSR1 rearrangement is diagnostically useful.

Differential Diagnosis: Small Round Blue Cell Tumors

Diagnosis	Key Distinguishing Feature
Ewing sarcoma	Diaphyseal bone tumor; t(11;22); CD99-positive
Neuroblastoma	Adrenal medulla/sympathetic chain; elevated urinary catecholamine metabolites
Rhabdomyosarcoma	Skeletal muscle differentiation; desmin and myogenin positive
Lymphoblastic lymphoma/leukemia	Immature lymphoid markers such as TdT

Staging Concepts and Prognosis

For Step 1, the most important staging distinction is localized versus metastatic disease. Prognosis is better for localized tumors of the extremities than for pelvic tumors or metastatic disease. Approximate 5-year survival is 70%–80% for localized disease with modern multimodal therapy, but falls to roughly 20%–40% with metastatic disease, especially when bone or bone marrow metastases are present. Adverse prognostic factors include large tumor volume, axial/pelvic location, elevated LDH, older age, poor histologic response to chemotherapy, and metastasis at presentation.

Treatment Principles and Pharmacology Correlation

Ewing sarcoma is treated with multimodal therapy: systemic chemotherapy plus local control with surgery and/or radiation. Chemotherapy is essential because micrometastatic disease is presumed even when imaging appears localized. Common regimens include alternating VDC/IE: vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide.

Drug	Mechanism	High-Yield Toxicity
Vincristine	Inhibits microtubule polymerization	Peripheral neuropathy, constipation
Doxorubicin	Topoisomerase II inhibitor; free radical formation	Dilated cardiomyopathy; risk rises at cumulative doses >450–550 mg/m²
Cyclophosphamide/Ifosfamide	Alkylating agents causing DNA cross-linking	Hemorrhagic cystitis; prevented with mesna
Etoposide	Topoisomerase II inhibitor	Myelosuppression; therapy-related AML risk

Radiation is effective for local control because Ewing sarcoma is radiosensitive; typical definitive doses are approximately 45–55.8 Gy, depending on resection status and anatomic constraints. A key Children’s Oncology Group trial, AEWS0031, showed that interval-compressed chemotherapy every 2 weeks rather than every 3 weeks improved 5-year event-free survival, approximately 73% versus 65%, supporting modern intensified scheduling with growth-factor support.

For exam purposes, the classic integrated diagnosis is: adolescent + painful diaphyseal bone mass + fever + onion-skin periosteal reaction + small round blue cells + t(11;22).

Chondrosarcoma

Chondrosarcoma is a malignant bone tumor in which neoplastic cells produce cartilaginous matrix. It is classically a tumor of adults older than 40 years, contrasting with osteosarcoma and Ewing sarcoma, which are more typical in children and adolescents. It is the second most common primary malignant bone tumor after osteosarcoma and most often involves the pelvis, proximal femur, proximal humerus, ribs, and shoulder girdle.

Pathogenesis and Molecular Mechanisms

Normal cartilage is produced by chondrocytes, which sit in lacunae and synthesize extracellular matrix rich in type II collagen and proteoglycans. In chondrosarcoma, malignant chondrocytes produce abnormal cartilage-like matrix and progressively invade bone marrow, cortex, and soft tissue. Unlike osteosarcoma, the malignant matrix is cartilage, not osteoid.

Many central conventional chondrosarcomas and enchondromas have mutations in IDH1 or IDH2. These mutations produce the oncometabolite 2-hydroxyglutarate, which inhibits α-ketoglutarate–dependent dioxygenases, alters DNA/histone methylation, and impairs normal cellular differentiation. Secondary peripheral chondrosarcomas may arise from osteochondromas, especially in hereditary multiple exostoses, which involves germline mutations in EXT1 or EXT2. EXT genes are required for heparan sulfate synthesis; defective signaling regulation contributes to abnormal cartilage-capped bony outgrowths.

Classification

Subtype	Typical Setting	High-Yield Features
Conventional central chondrosarcoma	Arises within medullary cavity	Most common; adults 40–70 years; pelvis and long bones
Peripheral chondrosarcoma	Arises from cartilage cap of osteochondroma	Concern if cartilage cap is >2 cm in adults or lesion grows after skeletal maturity
Dedifferentiated chondrosarcoma	Older adults	Low-grade cartilage tumor abruptly adjacent to high-grade sarcoma; very poor prognosis
Mesenchymal chondrosarcoma	Younger patients	Small round blue cell component plus cartilage; more chemo-sensitive than conventional type
Clear cell chondrosarcoma	Epiphysis of long bones	Low-grade but locally recurrent; may mimic chondroblastoma

Clinical Presentation

Patients typically present with deep, progressive pain and sometimes a palpable mass. Pain may occur at rest or at night, reflecting malignant behavior rather than purely mechanical symptoms. Pelvic tumors may grow large before detection because the pelvis has substantial space for expansion. Pathologic fracture can occur but is less characteristic than in lytic metastatic disease or multiple myeloma.

Malignant transformation of a solitary osteochondroma is uncommon, usually <1%. In hereditary multiple exostoses, the lifetime risk is higher, often cited around 2–5% and in some series up to 10%. Red flags include new pain, rapid growth, irregular mineralization, and cartilage cap thickness >2 cm in an adult.

Imaging and Gross Pathology

Radiographs often show a destructive, expansile lesion with “rings-and-arcs” calcification, reflecting mineralized hyaline cartilage. Additional findings include endosteal scalloping, cortical thickening or breakthrough, and soft-tissue extension. MRI is useful for defining marrow and soft-tissue involvement; cartilage has high water content, so tumors are often bright on T2-weighted images.

Grossly, the tumor appears bluish-white, translucent, and lobulated, resembling cartilage. Necrosis, myxoid change, and hemorrhage are more common in higher-grade tumors.

Histology and Grading

Microscopy shows malignant chondrocytes in lacunae embedded in cartilaginous matrix. Key features include increased cellularity, nuclear enlargement, hyperchromasia, binucleation, permeation of host bone, and mitotic activity. Histologic grade is one of the most important prognostic factors.

Grade	Histologic Features	Metastatic Risk and Prognosis
Grade 1	Mild atypia, low cellularity, rare mitoses	Low metastatic risk; 5-year survival often >90%
Grade 2	Moderate cellularity and atypia; myxoid matrix may be present	Intermediate risk; 5-year survival approximately 70–80%
Grade 3	Marked atypia, high cellularity, mitoses, necrosis	High metastatic risk; 5-year survival approximately 40–60%
Dedifferentiated	Low-grade cartilage tumor adjacent to high-grade noncartilaginous sarcoma	Very poor; 5-year survival often 10–25%

Staging and Spread

For Step 1, know that chondrosarcoma spreads primarily by hematogenous metastasis to the lungs. Regional lymph node spread is uncommon. The Enneking staging system for musculoskeletal tumors integrates grade, anatomic compartment, and metastasis: stage I is low grade, stage II is high grade, and stage III indicates metastatic disease; “A” is intracompartmental and “B” is extracompartmental.

Differential Diagnosis

Entity	Distinguishing Features
Enchondroma	Benign cartilage tumor of medullary cavity; often hands/feet; less pain, less endosteal scalloping
Osteosarcoma	Malignant osteoid production; metaphysis around knee; sunburst periosteal reaction, Codman triangle
Chondroblastoma	Benign epiphyseal tumor in adolescents; chicken-wire calcification
Metastatic carcinoma	Older adults; often multiple lesions; prostate blastic, kidney/thyroid/lung often lytic

Treatment Principles and Pharmacology Correlation

The major treatment principle is complete surgical excision with wide margins. Conventional chondrosarcoma is relatively resistant to chemotherapy and conventional fractionated radiotherapy because cartilage tumors often have low mitotic activity, poor vascularity, and abundant extracellular matrix, limiting drug delivery and radiation sensitivity. Radiation may be considered for unresectable tumors or positive margins, especially in anatomically difficult sites such as the skull base or pelvis.

Targeted therapy is not a core Step 1 requirement, but it illustrates mechanism-based oncology: ivosidenib, an IDH1 inhibitor, is given at 500 mg orally once daily for susceptible IDH1-mutant advanced tumors; its terminal half-life is approximately 93 hours. For exams, the higher-yield point is that chondrosarcoma is primarily a surgical disease, unlike Ewing sarcoma, which is highly chemotherapy-responsive.

Liposarcoma

Liposarcoma is a malignant soft-tissue sarcoma showing adipocytic differentiation. It is one of the most common adult soft-tissue sarcomas and classically presents in patients aged 40–60 years as a deep, painless, enlarging mass, most often in the thigh or retroperitoneum. Unlike benign lipoma, liposarcoma typically arises in deep soft tissue rather than superficial subcutaneous fat. Step 1 emphasis is on recognizing the histologic subtypes, characteristic molecular alterations, and clinical behavior.

Pathogenesis and Molecular Genetics

Normal adipocytes store triglycerides in a large lipid droplet that displaces the nucleus peripherally. In liposarcoma, malignant mesenchymal cells acquire adipocytic features but show atypia, uncontrolled proliferation, and invasive growth. A key microscopic clue is the lipoblast: a malignant cell with cytoplasmic lipid vacuoles that indent or “scallop” the hyperchromatic nucleus.

Subtype	Typical Site/Behavior	High-Yield Genetics	Key Histology
Well-differentiated liposarcoma / atypical lipomatous tumor	Deep extremity or retroperitoneum; locally aggressive, low metastatic risk	MDM2 and CDK4 amplification on chromosome 12q13–15	Mature adipocytes with variation in cell size, atypical stromal cells, scattered lipoblasts
Dedifferentiated liposarcoma	Often retroperitoneal; higher-grade component with metastatic potential	Also MDM2/CDK4 amplification	Well-differentiated liposarcoma adjacent to nonlipogenic high-grade sarcoma
Myxoid liposarcoma	Deep thigh; intermediate behavior; more radiosensitive	t(12;16) producing FUS-DDIT3; less commonly t(12;22) with EWSR1-DDIT3	Myxoid matrix, delicate “chicken-wire” capillaries, lipoblasts
Pleomorphic liposarcoma	Older adults; aggressive, high metastatic risk	Complex karyotype; usually no MDM2 amplification	Marked pleomorphism, bizarre giant cells, pleomorphic lipoblasts

MDM2 inhibits p53, a tumor suppressor that normally promotes DNA repair, cell-cycle arrest, or apoptosis after genomic damage. Amplification of MDM2 therefore functionally suppresses p53 activity. CDK4 promotes the G1-to-S phase cell-cycle transition by phosphorylating retinoblastoma protein. These mechanisms explain why MDM2 and CDK4 immunohistochemistry or fluorescence in situ hybridization are useful for distinguishing well-differentiated liposarcoma from lipoma.

Clinical Presentation and Imaging

Patients often report a slowly enlarging, painless mass. Concerning features of a soft-tissue mass include size >5 cm, deep location relative to fascia, rapid growth, pain, or recurrence after excision. Retroperitoneal tumors may grow very large before detection and can cause abdominal fullness, early satiety, ureteral obstruction, or venous compression.

MRI is the preferred local imaging modality for extremity soft-tissue sarcoma because it defines anatomic compartments, neurovascular involvement, and relationship to muscle and fascia. Liposarcoma may show fat signal, but features suggesting malignancy include thick septa, nodular nonfatty components, enhancement, and large size. Chest CT is commonly used for staging because many soft-tissue sarcomas metastasize hematogenously to the lungs.

Staging, Grading, and Prognosis

Soft-tissue sarcoma prognosis depends strongly on histologic grade, size, depth, anatomic site, and metastasis. The FNCLCC grading system scores tumor differentiation, mitotic count, and necrosis; higher scores indicate more aggressive biology. AJCC staging for extremity/trunk soft-tissue sarcoma incorporates grade plus tumor size: T1 ≤5 cm, T2 >5 to ≤10 cm, T3 >10 to ≤15 cm, and T4 >15 cm. Lymph node spread is uncommon in most liposarcomas; hematogenous lung metastasis is more typical, especially for high-grade pleomorphic and dedifferentiated tumors.

Diagnosis and Treatment Principles

Diagnosis requires tissue, typically by core needle biopsy planned so the biopsy tract can be excised during definitive surgery. This avoids contaminating uninvolved tissue planes. Definitive treatment is usually wide surgical excision with negative margins. Radiation is often used for large, deep, or high-grade extremity sarcomas; common regimens are approximately 50 Gy preoperatively or 60–66 Gy postoperatively, balancing local control against wound complications and fibrosis.

Systemic therapy is mainly relevant for unresectable, metastatic, or high-risk disease. Classic sarcoma chemotherapy includes doxorubicin 75 mg/m² IV every 3 weeks, limited by dose-dependent cardiomyopathy with cumulative risk rising around 450–550 mg/m². Ifosfamide may be combined with doxorubicin in selected high-risk settings. Liposarcoma-specific active agents include trabectedin 1.5 mg/m² as a 24-hour IV infusion every 3 weeks, particularly active in myxoid liposarcoma, and eribulin 1.4 mg/m² IV on days 1 and 8 of a 21-day cycle, which improved overall survival in previously treated liposarcoma in a phase III trial. For Step 1, however, the highest-yield point is that liposarcoma is a malignant adipocytic tumor with subtype-specific genetics, especially MDM2/CDK4 amplification and FUS-DDIT3 translocation.

Multiple Myeloma Bone Disease

Multiple myeloma is a malignant neoplasm of clonal plasma cells that primarily involves the bone marrow and causes destructive osteolytic bone disease. Plasma cells are terminally differentiated B cells that normally secrete immunoglobulin; in myeloma, a single clone produces a monoclonal immunoglobulin or light chain called an M protein. Bone disease is central to morbidity and is classically associated with bone pain, pathologic fractures, hypercalcemia, and “punched-out” lytic lesions of the skull, vertebrae, ribs, pelvis, and proximal long bones.

Pathophysiology of Bone Destruction

Unlike osteoblastic metastases, myeloma bone lesions are driven by increased osteoclast activity with suppressed osteoblast activity. Malignant plasma cells and marrow stromal cells produce cytokines that shift bone remodeling toward resorption.

• RANKL upregulation: Myeloma cells increase expression of receptor activator of nuclear factor κB ligand (RANKL), which binds RANK on osteoclast precursors and promotes osteoclast differentiation.
• OPG suppression: Osteoprotegerin (OPG) is a decoy receptor that normally binds RANKL; reduced OPG removes inhibition of osteoclastogenesis.
• IL-6: A key plasma-cell growth and survival factor; also supports osteoclast activation. IL-6 is high-yield for Step 1 as a growth factor in multiple myeloma.
• DKK1 and sclerostin: These inhibit Wnt signaling, suppressing osteoblast differentiation. Therefore, lesions are purely lytic with minimal reactive bone formation.

Because lesions are predominantly osteolytic and lack osteoblastic activity, technetium bone scans may be falsely negative. Plain radiographs show sharply demarcated “punched-out” lesions, especially in the skull. Low-dose whole-body CT, PET/CT, or MRI is more sensitive; modern criteria accept ≥1 osteolytic lesion ≥5 mm on CT or PET/CT as myeloma-defining bone disease.

Diagnostic Framework

Diagnosis requires evidence of clonal plasma-cell proliferation plus end-organ damage or biomarkers predicting imminent damage. Bone marrow shows ≥10% clonal plasma cells or a biopsy-proven plasmacytoma. Plasma cells have eccentric nuclei, “clock-face” chromatin, and a perinuclear hof representing the Golgi apparatus.

Category	High-yield criteria
MGUS	M protein <3 g/dL, marrow plasma cells <10%, no CRAB features; progression risk about 1% per year.
Smoldering myeloma	M protein ≥3 g/dL and/or marrow plasma cells ≥10%, but no myeloma-defining event.
Multiple myeloma	Clonal plasma cells ≥10% or plasmacytoma plus CRAB feature or SLiM biomarker.

CRAB features define symptomatic disease: Calcium >11 mg/dL or >1 mg/dL above upper limit of normal; Renal dysfunction with creatinine >2 mg/dL or creatinine clearance <40 mL/min; Anemia with hemoglobin <10 g/dL or >2 g/dL below normal; Bone lesions, including lytic lesions or pathologic fractures. The SLiM biomarkers are marrow plasma cells ≥60%, involved/uninvolved free light-chain ratio ≥100 with involved chain ≥100 mg/L, or >1 focal MRI lesion ≥5 mm.

Clinical and Laboratory Associations

• Bone pain: Often back or rib pain due to vertebral compression fractures or lytic lesions.
• Hypercalcemia: Normal serum calcium is approximately 8.5–10.5 mg/dL; symptoms include constipation, polyuria, confusion, and nephrolithiasis.
• Renal injury: Filtered light chains cause cast nephropathy; urine may contain Bence Jones proteins.
• Infections: Suppression of normal immunoglobulins predisposes to encapsulated organisms such as Streptococcus pneumoniae.
• Peripheral smear: Increased serum protein causes rouleaux formation, where RBCs stack like coins.
• Electrophoresis: Serum protein electrophoresis shows an M spike, often IgG, followed by IgA; light-chain-only disease may be detected by urine protein electrophoresis or serum free light-chain assay.

Staging and Prognostic Markers

The Revised International Staging System uses tumor burden, nutritional/inflammatory status, cytogenetics, and LDH. Stage I requires β2-microglobulin <3.5 mg/L, albumin ≥3.5 g/dL, normal LDH, and no high-risk cytogenetics. Stage III includes β2-microglobulin ≥5.5 mg/L plus high-risk cytogenetics or high LDH. High-risk abnormalities include del(17p), t(4;14), and t(14;16). β2-microglobulin reflects tumor burden and renal function.

Bone-Targeted Pharmacology

Myeloma bone disease is treated with antiresorptive agents that inhibit osteoclast-mediated bone loss. High-yield toxicities are testable.

Drug	Typical dose	Mechanism and key adverse effects
Zoledronic acid	4 mg IV every 3–4 weeks	Nitrogen-containing bisphosphonate; inhibits farnesyl pyrophosphate synthase in osteoclasts. Risks: renal toxicity, hypocalcemia, osteonecrosis of the jaw.
Pamidronate	90 mg IV every 3–4 weeks	Bisphosphonate with similar osteoclast inhibition; used cautiously in renal impairment.
Denosumab	120 mg subcutaneously every 4 weeks	Monoclonal antibody against RANKL; not renally cleared but can cause hypocalcemia and osteonecrosis of the jaw.

For Step 1, the unifying concept is that multiple myeloma causes multifocal osteolytic lesions through osteoclast activation and osteoblast inhibition, producing bone pain, fractures, hypercalcemia, and classic punched-out radiographic defects.

Giant Cell Tumor

Giant cell tumor of bone (GCTB), historically called osteoclastoma, is a benign but locally aggressive primary bone tumor characterized by numerous osteoclast-like multinucleated giant cells admixed with neoplastic mononuclear stromal cells. It accounts for approximately 5% of primary bone tumors and classically occurs in skeletally mature adults 20–40 years old, after closure of the growth plate. This age and location are high-yield: GCTB arises in the epiphysis of long bones, most often around the knee, especially the distal femur and proximal tibia; other sites include the distal radius and sacrum.

Pathogenesis and Molecular Mechanism

The true neoplastic component is the mononuclear stromal cell population, not the multinucleated giant cells. These stromal cells overexpress RANKL (receptor activator of nuclear factor-κB ligand), which binds RANK on osteoclast precursors and macrophage-lineage cells. This drives differentiation into osteoclast-like giant cells, causing vigorous osteolysis. Thus, the tumor’s destructive radiographic appearance reflects excessive osteoclast-mediated bone resorption rather than malignant osteoid production.

A highly characteristic molecular lesion is mutation in H3F3A, most commonly H3.3 G34W, present in approximately 90% of conventional GCTB. This mutation is useful conceptually for Step 1 because it emphasizes that the stromal cells are clonal and neoplastic, while the giant cells are reactive but biologically destructive.

Clinical and Radiographic Features

Patients typically present with gradually progressive localized pain, swelling, decreased joint motion, or pathologic fracture. Because the lesion reaches the subarticular region, pain may mimic joint disease. Radiographs show an eccentric, expansile, lytic epiphyseal lesion extending to the subchondral bone, often described as having a “soap-bubble” appearance. There is usually no dense sclerotic rim, helping distinguish it from more indolent lesions.

Feature	Giant Cell Tumor
Typical age	20–40 years; after physeal closure
Typical location	Epiphysis of long bones; distal femur/proximal tibia common
Radiology	Eccentric, expansile, lytic “soap-bubble” lesion abutting subchondral bone
Histology	Uniformly distributed osteoclast-like giant cells among mononuclear stromal cells
Biology	Benign but locally aggressive; pulmonary metastases in approximately 1–6%

Histology

Microscopy shows numerous multinucleated giant cells with nuclei resembling those of the surrounding mononuclear stromal cells. The distribution of giant cells is relatively uniform, unlike aneurysmal bone cyst, in which giant cells are often clustered around hemorrhagic spaces. Mitotic activity may be present in stromal cells, but atypical mitoses are not expected in conventional GCTB. Hemorrhage, hemosiderin, and secondary aneurysmal bone cyst-like change may occur.

Classification and Staging

For examinations, staging is mainly used to convey local aggressiveness rather than metastatic risk.

System	Category	Description
Campanacci radiographic grading	Grade I	Well-marginated lesion with intact cortex and limited expansion
Campanacci radiographic grading	Grade II	Thinned, expanded cortex without obvious soft-tissue mass
Campanacci radiographic grading	Grade III	Cortical destruction with soft-tissue extension
Enneking benign staging	S1/S2/S3	Latent, active, or aggressive benign bone lesion

Differential Diagnosis

The most tested differential is other epiphyseal or giant-cell-rich lesions.

Entity	Distinguishing Clues
Chondroblastoma	Epiphyseal tumor in adolescents; chondroid matrix and “chicken-wire” calcification
Aneurysmal bone cyst	Metaphyseal expansile lesion; blood-filled spaces; fluid-fluid levels on MRI
Brown tumor of hyperparathyroidism	Reactive giant-cell lesion; elevated PTH, hypercalcemia; normal serum calcium is about 8.5–10.5 mg/dL
Osteosarcoma	Malignant osteoid production; metaphyseal predominance; sunburst periosteal reaction/Codman triangle

Treatment Correlation and Pharmacology

Definitive therapy is usually surgical, commonly intralesional curettage with local adjuvants such as high-speed burring, phenol, cryotherapy, argon beam, or polymethylmethacrylate cement. Curettage alone has local recurrence rates often cited around 25–50%; adjuvant techniques reduce recurrence to approximately 10–20%. Wide resection has lower recurrence, often <5–10%, but greater morbidity.

Denosumab is a monoclonal antibody against RANKL and is mechanistically logical because GCTB stromal cells drive osteoclastogenesis through the RANK/RANKL pathway. It is used for unresectable disease or when surgery would cause major morbidity. A typical adult regimen is 120 mg subcutaneously every 4 weeks, with additional loading doses on days 8 and 15 of the first month. Its elimination half-life is approximately 25–28 days. Calcium and vitamin D supplementation are used to reduce hypocalcemia risk. Important adverse effects include hypocalcemia, osteonecrosis of the jaw, atypical femoral fracture, and rebound hypercalcemia after discontinuation, particularly in younger patients.

In a phase II study by Thomas et al., denosumab produced tumor response in about 86% of evaluable patients with recurrent or unresectable GCTB, supporting its role as targeted anti-osteoclast therapy. For Step 1, the key concept is that denosumab blocks RANKL, thereby suppressing the osteoclast-like giant cells responsible for bone destruction.